A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan.

Abstract

BACKGROUND:

A previously published proof of principle phase IIa trial with 113 patients from Kabul showed that bipolar high-frequency (HF) electro-cauterization (EC) of cutaneous leishmaniasis (CL) ulcers and subsequent moist wound treatment (MWT) closed 85% of all Leishmania (L.) tropica lesions within 60 days.

METHODS:

A three-armed phase IIb, randomized and controlled clinical trial was performed in Mazar-e-Sharif. L. tropica- or L. major-infected CL patients received intradermal sodium stibogluconate (SSG) (Group I); HF-EC followed by MWT with 0.045% DAC N-055 (Group II); or MWT with 0.045% DAC N-055 in basic crème alone (Group III). The primary outcome was complete epithelialisation before day 75 after treatment start.

RESULTS:

87 patients enrolled in the trial were randomized into group I (n = 24), II (n = 32) and III (n = 31). The per-protocol analysis of 69 (79%) patients revealed complete epithelialisation before day 75 in 15 (of 23; 65%) patients of Group I, in 23 (of 23; 100%) patients of Group II, and in 20 (of 23; 87%) patients of Group III (p = 0.004, Fisher's Exact Test). In the per-protocol analysis, wound closure times were significantly different between all regimens in a pair-wise comparison (p = 0.000039, Log-Rank (Mantel-Cox) test). In the intention-to-treat analysis wound survival times in Group II were significantly different from those in Group I (p = 0.000040, Log-Rank (Mantel-Cox) test). Re-ulcerations occurred in four (17%), three (13%) and seven (30%) patients of Group I, II or III, respectively (p = 0.312, Pearson Chi-Square Test).

CONCLUSIONS:

Treatment of CL ulcers with bipolar HF-EC followed by MWT with 0.045% DAC N-055 or with DAC N-055 alone showed shorter wound closure times than with the standard SSG therapy. The results merit further exploration in larger trials in the light of our current knowledge of in vitro and in vivo activities of chlorite. Clinicaltrials.gov ID: NCT00996463. Registered: 15th October 2009.

• Authors: Hans-Christian Stahl, Faridullah Ahmadi, Ulrike Schleicher, Rainer Sauerborn, Justo Lorenzo Bermejo, Mohammed Latif Amirih, Ibrahim Sakhayee, Christian Bogdan, Kurt-Wilhelm Stahl
• Journal: BMC infectious diseases (BMC Infect Dis) Vol. 14 Pg. 619 (Nov 25 2014) ISSN: 1471-2334 [Electronic] England
• PMID: 25420793 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiprotozoal Agents
• Chlorides
• Antimony Sodium Gluconate
• chlorite

Topics

• Adult
• Afghanistan
• Antimony Sodium Gluconate (therapeutic use)
• Antiprotozoal Agents (therapeutic use)
• Bandages
• Chlorides (therapeutic use)
• Electrocoagulation (methods)
• Female
• Humans
• Injections, Intralesional
• Leishmaniasis, Cutaneous (complications, therapy)
• Male
• Skin Ulcer (etiology, therapy)
• Time Factors
• Treatment Outcome
• Wound Healing
• Young Adult